|Bid||123.74 x 600|
|Ask||123.75 x 200|
|Day's Range||123.37 - 124.42|
|52 Week Range||99.57 - 125.37|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.20%|
There’s no question about it — growth stocks have been the place to be during this bull market. However, according to LPL analyst Burt White, the growth trade may have finally run its course in 2017 . ...
Regeneron and Sanofi have submitted an application seeking regulatory approval for Kevzara in Japan.
Becton Dickinson accelerated its strategy to establish itself as the leader in single cell genomics with its recent launch of BD Rhapsody, a single cell analysis platform.